NALO Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Out of Business

NALO Therapeutics General Information

Description

Developer of pharmaceutical products intended to treat hematological and solid tumors. The company's products are small molecule-based medicines for the treatment of cancer and are high-value disease drivers and target major unmet needs in oncology, enabling patients with medicines to treat cancer cells that originate from uncontrolled cellular growth.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 628 Middlefield Road
  • Palo Alto, CA 94301
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 628 Middlefield Road
  • Palo Alto, CA 94301
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NALO Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 03-Oct-2025 Completed Out of Business
2. Early Stage VC 01-May-2020 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view NALO Therapeutics’s complete valuation and funding history, request access »

NALO Therapeutics Patents

NALO Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025175145-A1 N-(1-((r)-1-acryloylazepan-3-yl)-7-chloro-6-(((r)-tetrahydrofuran-3-yl)oxy)-1h-b enzo[d]imidazol-2-yl)-2-methylisonicotinamide (nx-019) for use in the treatment of egfr mutant cancer Pending 14-Feb-2024
WO-2025043063-A1 Modulators of myc family proto-oncogene protein Inactive 24-Aug-2023
WO-2025043065-A1 Modulators of myc family proto-oncogene protein Inactive 24-Aug-2023
WO-2024206628-A1 Modulators of myc family proto-oncogene protein Inactive 30-Mar-2023
WO-2024206628-A4 Modulators of myc family proto-oncogene protein Inactive 30-Mar-2023 C07D493/08
To view NALO Therapeutics’s complete patent history, request access »

NALO Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NALO Therapeutics FAQs

  • When was NALO Therapeutics founded?

    NALO Therapeutics was founded in 2017.

  • Where is NALO Therapeutics headquartered?

    NALO Therapeutics is headquartered in Palo Alto, CA.

  • What is the size of NALO Therapeutics?

    NALO Therapeutics has 6 total employees.

  • What industry is NALO Therapeutics in?

    NALO Therapeutics’s primary industry is Drug Discovery.

  • Is NALO Therapeutics a private or public company?

    NALO Therapeutics is a Private company.

  • What is NALO Therapeutics’s current revenue?

    The current revenue for NALO Therapeutics is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process